Degradomic Identification of Membrane Type 1-Matrix Metalloproteinase as an ADAMTS9 and ADAMTS20 Substrate.

ADAM ADAMTS MMP MT1-MMP cleavage degradome degradomics focal adhesion gene-editing-N-terminomics metalloprotease protease proteolysis substrate

Journal

Molecular & cellular proteomics : MCP
ISSN: 1535-9484
Titre abrégé: Mol Cell Proteomics
Pays: United States
ID NLM: 101125647

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 14 09 2022
revised: 05 05 2023
accepted: 07 05 2023
medline: 26 6 2023
pubmed: 12 5 2023
entrez: 11 5 2023
Statut: ppublish

Résumé

The secreted metalloproteases ADAMTS9 and ADAMTS20 are implicated in extracellular matrix proteolysis and primary cilium biogenesis. Here, we show that clonal gene-edited RPE-1 cells in which ADAMTS9 was inactivated, and which constitutively lack ADAMTS20 expression, have morphologic characteristics distinct from parental RPE-1 cells. To investigate underlying proteolytic mechanisms, a quantitative terminomics method, terminal amine isotopic labeling of substrates was used to compare the parental and gene-edited RPE-1 cells and their medium to identify ADAMTS9 substrates. Among differentially abundant neo-amino (N) terminal peptides arising from secreted and transmembrane proteins, a peptide with lower abundance in the medium of gene-edited cells suggested cleavage at the Tyr

Identifiants

pubmed: 37169079
pii: S1535-9476(23)00076-2
doi: 10.1016/j.mcpro.2023.100566
pmc: PMC10267602
pii:
doi:

Substances chimiques

Hemopexin 9013-71-2
Matrix Metalloproteinase 14 EC 3.4.24.80
Peptides 0
ADAMTS20 protein, human EC 3.4.24.-
ADAMTS9 protein, human EC 3.4.24.-
MMP14 protein, human EC 3.4.24.80

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100566

Subventions

Organisme : NIDDK NIH HHS
ID : R01 DK126804
Pays : United States

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare no competing interests.

Auteurs

Sumeda Nandadasa (S)

Department of Biomedical Engineering, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio, USA; Department of Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts, USA. Electronic address: Sumeda.Nandadasa@Umassmed.edu.

Daniel Martin (D)

Department of Biomedical Engineering, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio, USA.

Gauravi Deshpande (G)

Imaging Core Facility, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio, USA.

Karyn L Robert (KL)

Department of Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

M Sharon Stack (MS)

Department of Chemistry and Biochemistry and Harper Cancer Center, University of Notre Dame, Notre Dame, Indiana, USA.

Yoshifumi Itoh (Y)

Kennedy Institute for Rheumatology, University of Oxford, Oxford, UK.

Suneel S Apte (SS)

Department of Biomedical Engineering, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio, USA. Electronic address: aptes@ccf.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH